Completed
Phase 4
Age: 18Years +
All Genders
ID00277472
A 28-week, Multicenter Study to Evaluate the Effects of ValsartanHydrochlorothiazide 16012.5 mg in Comparison With Hydrochlorothiazide 25 mg Monotherapy, for the Treatment of Patients With Hypertension, Uncontrolled by Hydrochlorothiazide 12.5 mg Monotherapy
Led by Novartis · Updated on 2011-06-07
300
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.
CONDITIONS
Brief Title
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
Inclusion Criteria:
- Male or female 18 years of age and older
- Diagnosed as having hypertension (mean seated systolic blood pressure ≥ 150 mm Hg but < 180 mm Hg and mean seated diastolic blood pressure ≥ 95 mm Hg and <110 mm Hg
Exclusion Criteria:
- - Patients with sever hypertension: Systolic ≥ 180 mm Hg or Diastolic ≥ 110 mm Hg
- Diabetes with fasting glucose > 126 mg/dl or on existing anti-diabetic medication
- History of stroke, transient ischemic attack, or myocardial infarction within the last 6 months, or diagnosed with congestive heart failure.
Other protocol-defined inclusion/exclusion criteria may apply.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here